Breast Cancer Update

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Breast Cancer Update is a science podcast hosted by Dr. Neil Love, with 113 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Dr. Neil Love hosts Breast Cancer Update, a science show with 113 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #74

  For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress

  Aug 18, 20261h 28mS25

  Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: Introduction (0:00) Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) Practical Considerations with Oral SERDs (15:43) Potential Role of Combination Approaches with Oral SERDs (26:33) Gastrointestinal Adverse Events Documented with Oral SERDs (38:19) Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54) Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56) Emerging Utility of Adjuvant Oral SERDs (1:10:20) Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22) CME information and select publications

  ListenShow Notes
• 

  Episode #73

  For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress

  Aug 10, 20261h 30mS25

  Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) Clinical Utility of Capivasertib for HR-Positive mBC (38:09) Mitigation and Management of Gastrointestinal Adverse Events (51:05) Management of Dermatologic Adverse Events (59:58) Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42) Monitoring and Management of Cytopenias (1:21:23) CME information and select publications

  ListenShow Notes
• 

  Episode #72

  For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

  Jul 29, 20261h 29mS25

  Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics: Introduction (00:00) Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24) Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52) Adjuvant CDK4/6 Inhibitor Therapy (17:14) Practical Considerations with CDK4/6 Inhibitors (29:57) Monitoring and Management of Cytopenias (42:02) CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32) Management of Gastrointestinal Adverse Events (1:03:47) CDK4/6 Inhibitors in Unique Populations (1:10:41) Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48) CME information and select publications

  ListenShow Notes
• 

  Episode #71

  Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

  Jul 25, 20261h 58mS25

  Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications

  ListenShow Notes
• 

  Episode #70

  HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

  Jul 18, 202646 minS25

  Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00) Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35) Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01) Targeting the PI3K signaling pathway in HER2-positive mBC (11:08) Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53) Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44) Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54) Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications

  ListenShow Notes

Recent guests on Breast Cancer Update. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.